Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diabres.2016.10.002PMID 27835765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

  2016cited by this paper
• A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes—JDCP study 2

  2016cited by this paper
• New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

  2016cited by this paper
• Abstracts from ATTD 20158th International Conference on Advanced Technologies & Treatments for DiabetesParis, France—February 18–21, 2015

  2015cited by this paper
• Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL−1 and Glargine 100 U mL−1 in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study

  2015cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

  2015cited by this paper
• New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

  2015cited by this paper
• 7. Approaches to Glycemic Treatment

  2015cited by this paper
• Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

  2014cited by this paper
• Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

  2014cited by this paper
• New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

  2014cited by this paper
• Type 1 diabetes.

  2014cited by this paper
• ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

  2013cited by this paper
• Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

  2012cited by this paper
• Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era

  2011cited by this paper
• Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes

  2009cited by this paper
• Comparison of a Multiple Daily Insulin Injection Regime (Basal Once-Daily Glargine plus Mealtime Lispro) and CSII (Lispro) in Type 1 Diabetes: a Randomized Open Parallel Multicenter Study

  2009cited by this paper
• Multifaceted Determinants for Achieving Glycemic Control

  2009cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• Hypoglycemia in diabetes.

  2003cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2000cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper

• International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes

  2025cites this paper
• Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes

  2024cites this paper
• Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review

  2024cites this paper
• Current and Future Strategies in Insulin Development and Treatment

  2024cites this paper
• Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US)

  2023cites this paper
• Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis

  2023cites this paper
• Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review

  2023cites this paper
• Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison

  2022influential citation
• ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes

  2022cites this paper
• Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study

  2020cites this paper
• Special aspects of concentrated insulins: basic characteristics and research findings

  2020cites this paper
• Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)

  2020cites this paper
• Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different

  2019cites this paper
• Comparative effectiveness and harms of long‐acting insulins for type 1 and type 2 diabetes: A systematic review and meta‐analysis

  2019cites this paper
• Patient Assessment in Clinical Pharmacy

  2019cites this paper
• Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus

  2019cites this paper
• Glycemic Management in Adults With Type 1 Diabetes.

  2018cites this paper
• Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature

  2018cites this paper
• Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

  2018cites this paper
• Understanding concentrated insulins: a systematic review of randomized controlled trials

  2018cites this paper
• Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis

  2018cites this paper
• High Concentration Insulin

  2018influential citation
• Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

  2017cites this paper
• Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)

  2017influential citation
• Insulin analogues in type 1 diabetes mellitus: getting better all the time

  2017cites this paper
• Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus

  2016cites this paper